Clarification of Optimal Anticoagulation Through Genetics

About The COAG Network

The Clarification of Optimal Anticoagulation Through Genetics (COAG) research network is conducting collaborative research to answer the question if the use of genetic and clinical information for selecting the dose of warfarin during the initial dosing period will lead to improvement in stability of anticoagulation (AC) relative to a strategy that incorporates only clinical information (without genetics) for the initial dosing period.

This national research network includes twelve Clinical Sites that will conduct the research study, a Clinical Trial Coordinating Center (CTCC) that will coordinate data collection and analysis, a central Drug Distribution Center that will package and coordinate study drug, and a Central Laboratory that will provide oversight for genomic procedures and provide technical support.

The COAG Research Network Clinical Sites include:

• University of Texas, Galveston, TX
• Mount Sinai School of Medicine, New York, NY
• University of California San Francisco, San Francisco, CA
• Washington University School of Medicine, St. Louis, MO
• University of Maryland School of Medicine, Baltimore, MD
• University of Florida, Gainesville, FL
• Henry Ford Hospital, Detroit, MI
• Mayo Clinic College of Medicine, Rochester, MN
• Hospital of the University of Pennsylvania, Philadelphia, PA
• Vanderbilt University, Nashville, TN
• Intermountain Medical Center, Murray, UT
• Marshfield Clinical Research Foundation, Marshfield, WI

The COAG Research Network Core Sites include:

• Clinical Trial Coordinating Center – University of Pennsylvania, Philadelphia, PA
• Drug Distribution Center – University of Pennsylvania, Philadelphia, PA
• Central Laboratory – Washington University, St. Louis, MO